[Federal Register Volume 69, Number 101 (Tuesday, May 25, 2004)]
[Notices]
[Page 29760]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 04-11758]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket No. 030-34781]


Notice of Availability of Environmental Assessment and Finding of 
No Significant Impact for License Amendment for Message 
Pharmaceuticals, Inc.'s Facility in Malvern, PA

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of Availability of Environmental Assessment and Finding 
of No Significant Impact.

-----------------------------------------------------------------------

FOR FURTHER INFORMATION CONTACT: Sattar Lodhi, Nuclear Materials Safety 
Branch 2, Division of Nuclear Materials Safety, Region I, 475 Allendale 
Road, King of Prussia, Pennsylvania, 19406, telephone (610) 337-5364 
fax (610) 337-5269; or by e-mail: asl@nrc.gov.

SUPPLEMENTARY INFORMATION:

I. Introduction

    The Nuclear Regulatory Commission (NRC) is considering the issuance 
of a license amendment to Message Pharmaceuticals, Inc.'s Materials 
License No. 37-30462-01, to authorize release of its facility in 
Malvern, Pennsylvania for unrestricted use. NRC has prepared an 
Environmental Assessment (EA) in support of this action in accordance 
with the requirements of 10 CFR part 51. Based on the EA, the NRC has 
concluded that a Finding of No Significant Impact (FONSI) is 
appropriate. The amendment will be issued following the publication of 
this Notice.

II. EA Summary

    The purpose of the proposed action is to authorize the release of 
the licensee's Malvern, Pennsylvania facility for unrestricted use. 
Message Pharmaceuticals, Inc., was authorized by NRC from July 29, 
1998, to use radioactive materials for research and development 
purposes at the site. On January 5, 2004, Message Pharmaceuticals, 
Inc., requested that NRC release the facility for unrestricted use. 
Message Pharmaceuticals, Inc., has conducted surveys of the facility 
and determined that the facility meets the license termination criteria 
in Subpart E of 10 CFR part 20. The NRC staff has prepared an EA in 
support of the proposed license amendment.

III. Finding of No Significant Impact

    The staff has prepared the EA (summarized above) in support of the 
proposed license amendment to terminate the license and release the 
facility for unrestricted use. The NRC staff has evaluated Message 
Pharmaceuticals, Inc.'s request and the results of the surveys and has 
concluded that the completed action complies with the criteria in 
Subpart E of 10 CFR part 20. The staff has found that the environmental 
impacts from the proposed action are bounded by the impacts evaluated 
by the ``Generic Environmental Impact Statement in Support of 
Rulemaking on Radiological Criteria for License Termination of NRC-
Licensed Facilities'' (NUREG-1496). On the basis of the EA, the NRC has 
concluded that the environmental impacts from the proposed action are 
expected to be insignificant and has determined not to prepare an 
environmental impact statement for the proposed action.

IV. Further Information

    The EA and the documents related to this proposed action, including 
the application for the license amendment and supporting documentation, 
are available for inspection at NRC's Public Electronic Reading Room at 
http://www.nrc.gov/reading-rm/adams.html (ADAMS Accession Nos. 
ML040250011 and ML041040862). These documents are also available for 
inspection and copying for a fee at the Region I Office, 475 Allendale 
Road, King of Prussia, Pennsylvania, 19406. Persons who do not have 
access to ADAMS, should contact the NRC PDR Reference staff by 
telephone at 1-800-397-4209 or (301) 415-4737, of by e-mail to 
pdr@nrc.gov.

    For the Nuclear Regulatory Commission.

    Dated at King of Prussia, Pennsylvania this 18th day of May, 
2004.

John D. Kinneman,
Chief, Nuclear Materials Safety Branch 2, Division of Nuclear Materials 
Safety Region I .
[FR Doc. 04-11758 Filed 5-24-04; 8:45 am]
BILLING CODE 7590-01-P